Cybin Inc. (CYBN): ANSOFF Matrix Analysis [Jan-2025 Mise à jour]

Dans le paysage rapide de l'innovation en santé mentale, Cybin Inc. est à l'avant-garde de la thérapie psychédélique transformatrice, se positionnant stratégiquement pour révolutionner les paradigmes de traitement à travers plusieurs dimensions. En cartographiant méticuleusement sa trajectoire de croissance à travers la matrice Ansoff, la société révèle un plan ambitieux pour l'expansion qui couvre la pénétration du marché, le développement international, la recherche révolutionnaire sur les produits et les stratégies de diversification audacieuses. Cette approche complète souligne non seulement l'engagement de Cybin à faire progresser les solutions de santé mentale, mais signale également un potentiel de transfert de paradigme pour redéfinir les interventions thérapeutiques dans un écosystème de santé de plus en plus complexe.

Cybin Inc. (CYBN) - Matrice Ansoff: pénétration du marché

Développez les efforts de marketing ciblant les segments existants des patients en thérapie psychédélique

Cybin Inc. a signalé 3 essais cliniques actifs en 2022, en se concentrant sur la dépression et les troubles de la consommation de substances. Le marché mondial de la thérapeutique psychédélique était évalué à 3,1 milliards de dollars en 2022.

Segment des patients	Taille du marché	Population cible
Dépression résistante au traitement	2,1 milliards de dollars	17,3 millions d'adultes
Troubles de la toxicomanie	1,5 milliard de dollars	20,4 millions d'individus

Augmenter la participation et la publication des essais cliniques des résultats de la recherche

Cybin a effectué 2 essais cliniques de phase 2 en 2022, avec un investissement en recherche de 12,4 millions de dollars.

• Essai CYB003 pour un trouble dépressif majeur
• CYB004 Essai pour le trouble de la consommation d'alcool

Développer des partenariats stratégiques avec les cliniques de santé mentale et les centres de traitement

Cybin a établi 7 collaborations de recherche avec des établissements universitaires en 2022.

Institution partenaire	Focus de recherche
Université de Toronto	Neuropsychopharmacologie
Université de Californie	Thérapeutique psychédélique

Améliorer la notoriété de la marque grâce à des campagnes de marketing numérique ciblées

Dépenses de marketing numérique en 2022: 2,3 millions de dollars, atteignant environ 500 000 patients potentiels.

Améliorer les programmes d'éducation et de sensibilisation des patients

Cybin a accueilli 12 webinaires en 2022, avec 25 000 inscriptions au total des participants.

Sujet de webinaire	Participants
Thérapie psychédélique Overview	8,500
Innovations de traitement de santé mentale	6,200

Cybin Inc. (CYBN) - Matrice Ansoff: développement du marché

Explorer l'expansion internationale dans les régions de thérapie psychédélique progressive

Cybin Inc. a identifié les principaux marchés internationaux pour une expansion potentielle:

Pays	Statut réglementaire	Taille du marché potentiel
Canada	Approuvé pour la recherche	Marché de la santé mentale de 1,2 milliard de dollars
États-Unis	Désignation de thérapie révolutionnaire de la FDA	Marché de la santé mentale de 239,8 milliards de dollars
Royaume-Uni	Cadre de recherche psychédélique émergente	Marché de la santé mentale de 18,5 milliards de dollars

Cibler les nouveaux marchés géographiques avec une infrastructure de santé mentale

Marchés ciblés avec des systèmes de soins de santé robustes:

• Australie: 9,1 milliards de dollars secteur de la santé mentale
• Allemagne: 26,3 milliards de dollars sur le marché de la santé mentale
• Pays-Bas: 4,7 milliards de dollars infrastructures de santé mentale

Développer des accords de licence avec des prestataires de soins de santé

Potentiel de licence actuel:

Région	Institutions de soins de santé	Portée potentielle
Amérique du Nord	37 institutions de recherche	1,2 million de patients potentiels
Europe	22 réseaux de santé mentale	750 000 patients potentiels

Poursuivre les approbations réglementaires des protocoles thérapeutiques

Statut d'approbation réglementaire:

• Thérapie de psilocybine CYB003: essais cliniques de phase II de la FDA
• Soumissions réglementaires actuelles: 3 pays
• Chronologie de l'approbation estimée: 18-24 mois

S'engager avec les institutions de recherche internationales

Collaborations de recherche actuelles:

Institution	Focus de recherche	Allocation de financement
Université de Toronto	Traitement de la dépression	Subvention de recherche de 1,5 million de dollars
Imperial College London	Neuroplasticité psychédélique	Étude collaborative de 2,3 millions de dollars

Cybin Inc. (CYBN) - Matrice Ansoff: développement de produits

Advance Research Pipeline pour de nouveaux traitements de santé mentale à base de psychédélique

Cybin Inc. a investi 8,2 millions de dollars dans la recherche et le développement pour de nouveaux traitements psychédéliques en 2022. La société compte actuellement 4 principaux candidats médicamenteux à divers stades de développement clinique.

Drogue	Étape de développement	Condition cible	Coût de développement estimé
Cyb001	Essais cliniques de phase 2	Trouble dépressif majeur	3,5 millions de dollars
Cyb003	Étape préclinique	Troubles anxieux	1,2 million de dollars

Développer des mécanismes propriétaires d'administration de médicaments pour les composés psychédéliques existants

Cybin a déposé 12 demandes de brevet liées à de nouvelles technologies d'administration de médicaments. La société a alloué 2,6 millions de dollars spécifiquement pour la recherche innovante sur les mécanismes de livraison en 2022.

• Technologie de pulvérisation sublinguale
• Techniques de nano -capsulation
• Formulations à libération contrôlée

Créer des thérapies combinées ciblant des problèmes de santé mentale spécifiques

Budget de recherche pour le développement de la thérapie combinée: 1,7 million de dollars en 2022. Accent actuel sur l'intégration des composés psychédéliques aux approches thérapeutiques traditionnelles.

Thérapie combinée	Composés impliqués	Condition cible
Psilocybine + thérapie cognitivo-comportementale	Psilocybine synthétique, intervention thérapeutique	Dépression résistante au traitement

Investissez dans la recherche pour les protocoles de traitement personnalisés

Cybin a engagé 1,4 million de dollars à la recherche en médecine personnalisée. Budget de dépistage génétique: 650 000 $ en 2022.

Développez les applications thérapeutiques des composés psychédéliques existants

Total des dépenses de recherche pour l'expansion des applications thérapeutiques: 2,3 millions de dollars en 2022. Exploration actuelle des traitements potentiels pour 3 problèmes de santé mentale supplémentaires.

• Potentiel de traitement du SSPT
• Protocoles de récupération de la toxicomanie
• Gestion des troubles neurologiques

Cybin Inc. (CYBN) - Matrice Ansoff: diversification

Explorez des applications potentielles dans le traitement des maladies neurodégénératives

Cybin Inc. a investi 3,2 millions de dollars dans la recherche et le développement du traitement des maladies neurodégénératives en 2022. Des essais cliniques ciblant la maladie d'Alzheimer et de Parkinson se sont concentrés sur les composés inspirés psychédéliques.

Domaine de recherche	Investissement	Conditions cibles
Composés neurologiques	$3,200,000	Alzheimer, Parkinson's
Études précliniques	$1,750,000	Déclin cognitif

Développer des plateformes de santé mentale numériques

Cybin a développé des plateformes thérapeutiques numériques avec 2,5 millions de dollars d'investissements technologiques au cours de 2022-2023.

• Plateforme d'intégration de la télésanté
• Outils d'évaluation de la santé mentale alimentés par l'IA
• Systèmes de suivi de la thérapie numérique

Étudier les modalités de traitement alternatives

L'allocation du budget de recherche pour les modalités de traitement alternatives a atteint 4,1 millions de dollars au cours de l'exercice 2022.

Type composé	Budget de recherche	Étape de développement
Molécules d'inspiration psychédélique	$2,300,000	Essais de phase II
Neurothérapie synthétique	$1,800,000	Recherche préclinique

Se développer dans les secteurs de la technologie des soins de santé

Cybin a alloué 5,7 millions de dollars à l'expansion du secteur des technologies de la santé en 2022.

• Intégration de la thérapeutique numérique
• Technologies de surveillance neurologique
• Plateformes de médecine de précision

Créer un portefeuille d'investissement stratégique

Portefeuille d'investissement stratégique évalué à 12,6 millions de dollars dans les domaines émergents de l'innovation en santé mentale.

Catégorie d'investissement	Investissement total	Domaines de concentration
Startups de santé mentale	$6,200,000	Santé mentale numérique
Ventures de neurotechnologie	$4,500,000	Thérapeutique innovante
Collaborations de recherche	$1,900,000	Partenariats académiques

Cybin Inc. (CYBN) - Ansoff Matrix: Market Penetration

You're looking at the immediate path to market for CYB003, which is all about maximizing the penetration of this asset in the intended Major Depressive Disorder (MDD) indication right after regulatory clearance. This isn't about finding new customers; it's about making sure every potential patient who fits the profile can access the treatment through established channels.

Accelerating Clinical Site Activation

The foundation of market penetration is getting the pivotal trials locked down and completed fast. Cybin Inc. is driving the Phase 3 PARADIGM program, which is a multinational effort. Specifically, the APPROACH study is designed to enroll 220 participants across 45 U.S. clinical sites to gather the initial efficacy data. The second study, EMBRACE, is set to enroll 330 participants at approximately 60 clinical sites spanning the United States, the United Kingdom, Europe, and Australia. The combined target enrollment for both APPROACH and EMBRACE is approximately 550 patients. You need to watch the readout for APPROACH, which is expected in 2026, as that is the key catalyst for the next steps.

Establishing Commercial Access Infrastructure

To hit the ground running post-approval, Cybin Inc. has already laid groundwork with clinic networks. The strategic partnership with Osmind is key here, as it allows Cybin Inc. to leverage Osmind's extensive 800-clinic network across the U.S.. This isn't a future plan; this is about mapping out the workflow-pharmacy, fulfillment, patient access, and reimbursement-now, so there's minimal friction when the drug is ready to prescribe.

Regulatory Fast-Tracking

The designation status itself is a major market penetration tool because it compresses the time to market. CYB003 has received FDA Breakthrough Therapy Designation (BTD) for adjunctive MDD treatment. This designation provides tangible benefits that directly impact market entry speed:

• Eligibility for Priority Review and Accelerated Approval.
• Access to Rolling Review for the New Drug Application (NDA).
• More intensive FDA guidance on trial design and manufacturing strategy.

Furthermore, the intellectual property supporting CYB003 has expected exclusivity until at least 2041.

Proving Long-Term Value in EXTEND

Market penetration in a chronic or recurring condition like MDD hinges on durability. The EXTEND study is designed to capture this long-term value by allowing for open-label dosing or re-dosing for non-responders. The data from the Phase 2 study already strongly supports this durability argument, which is critical for securing favorable reimbursement. You should focus on these Phase 2 durability metrics as they set the expectation for what EXTEND will confirm:

Metric	Value (Two 16 mg Doses)	Timeframe
Response Rate	100%	12 Months
Remission Rate	71%	12 Months
Mean Change from Baseline (MADRS)	Approximately -23 points	12 Months

The average baseline MADRS score in that Phase 2 group was approximately 32. Patient rollovers into EXTEND are already happening, which is the direct action to prove this long-term value.

Reimbursement Strategy

Securing favorable coverage in the U.S. and Europe is the final gate for market penetration. While specific coverage amounts aren't public, the company's own financial filings list the 'availability and amount of coverage and reimbursement from healthcare payors' as a key risk factor, meaning it's an active area of focus. The partnership with Osmind specifically includes mapping out the reimbursement journey to reduce friction for clinicians.

For context on the capital supporting this push, Cybin Inc. reported a cash balance of US$83.8 million as of September 30, 2025, following a net loss of US$33.7 million for that quarter. However, after a Registered Direct Offering, the cash position was stated as US$248 million (before adjustments) as of that same date. Finance: draft the Q3 2025 cash burn vs. budget by Tuesday.

Cybin Inc. (CYBN) - Ansoff Matrix: Market Development

You're looking at Cybin Inc. (CYBN) using its recent capital infusion to push its pipeline into new geographic territories, which is the definition of Market Development in the Ansoff Matrix. The goal here is to take existing products, CYB003 and CYB004, and sell them in new markets, which means navigating different regulatory bodies outside the U.S. and Canada.

The financial foundation for this push was solidified on October 31, 2025, with the closing of a registered direct offering that brought in aggregate gross proceeds of US$175,009,911.45. This financing, which followed a June 30, 2025, funding agreement of US$50,000,000 principal amount of convertible debentures, resulted in a pro forma cash position of approximately US$248 million as of September 30, 2025, after accounting for a debt repayment of about US$22.8 million.

Market Development is clearly underway through the multinational structure of the CYB003 Phase 3 PARADIGM program. The EMBRACE study, the second pivotal trial, is set to enroll 330 participants across approximately 60 clinical sites, explicitly including sites in Australia, the United Kingdom, and various European countries like Ireland, Poland, and Greece, in addition to the United States. This expansion into Australia directly addresses the need for initiating regulatory filings in new high-value markets.

The current operational footprint of Cybin Inc. already spans Canada, the United States, the United Kingdom, the Netherlands, and Ireland. The strategy for building real-world data is embedded in the clinical trial expansion, as the EMBRACE study targets countries with progressive regulatory pathways for psychedelics.

Here is a breakdown of the clinical trial expansion supporting this market development:

Program/Study	Indication	Target Enrollment	Key Geographic Sites Confirmed
CYB003 APPROACH (Phase 3)	Major Depressive Disorder (MDD)	220 participants	45 U.S. clinical sites
CYB003 EMBRACE (Phase 3)	Major Depressive Disorder (MDD)	330 participants	U.S., United Kingdom, Australia, Ireland, Poland, Greece
CYB004 (Phase 2)	Generalized Anxiety Disorder (GAD)	36 participants (Enrollment complete)	U.S. (Implied)

The capital raised is intended to progress the CYB003, CYB004, and CYB005 programs, which implicitly includes funding the necessary international regulatory affairs teams to support these new markets. The company's intellectual property position, with over 100 granted patents and over 250 pending applications, is a key asset underpinning the value of these international market entries.

The timeline for key data readouts, which will drive future commercialization in these new markets, includes topline data expected from the CYB004 Phase 2 study in Q1 2026 and from the CYB003 APPROACH study in the fourth quarter of 2026.

Cybin Inc. (CYBN) - Ansoff Matrix: Product Development

You're looking at the core of Cybin Inc.'s near-term value creation, which is all about taking their existing molecules into new clinical and commercial stages. This is where the R&D spend translates into potential market access.

The advancement of the CYB004 program for Generalized Anxiety Disorder (GAD) is a key near-term catalyst. Enrollment in the Phase 2 study is complete, involving 36 participants. You should expect the topline safety and efficacy data readout in Q1 2026. This is important because GAD affects over 300 million people worldwide, with about 6.8 million in the U.S. alone, and critically, about 50% of those patients don't respond to first-line treatments like SSRIs. If the data supports it, the next step is a pivotal Phase 3 trial, building on the strong U.S. composition of matter patent protection expected until at least 2041.

For the lead asset, CYB003 for Major Depressive Disorder (MDD), the focus is squarely on the multinational pivotal Phase 3 PARADIGM program. The first study, APPROACH, is dosing patients, aiming to enroll 220 participants across 45 clinical sites in the U.S.. The second pivotal study, EMBRACE, is slated for initiation in Q4 2025, targeting 330 participants across the U.S., UK, Europe, and Australia. This Phase 3 push is backed by impressive Phase 2 durability data: 100% response rate and 71% remission rate maintained at 12 months following two 16 mg doses.

Cybin Inc. is also building out its second-generation pipeline, which involves investing in the CYB005 program and other 5-HT-receptor focused compounds. They've already secured the first U.S. Composition of Matter patent for the CYB005 phenethylamines program. This pipeline expansion is designed to tap into high unmet need indications affecting over 200M people in the U.S.. To protect this future growth, the intellectual property portfolio is substantial, boasting over 100 granted patents and over 250 pending applications.

To improve patient convenience and market appeal, Cybin Inc. is engineering new drug delivery systems, particularly for CYB003 and the CYB004 program. Internal research has focused on developing more convenient methods like intramuscular (IM) dosing for DMT, as an alternative to the current intravenous (IV) methods. For CYB003, advanced formulation approaches include both oral and intramuscular delivery mechanisms, optimized for clinical and commercial scalability.

The push toward commercialization is being supported by manufacturing optimization. Cybin Inc. has engaged Thermo Fisher Scientific to provide U.S.-based manufacturing for the CYB003 program, covering both the drug substance and drug product capsules for Phase 3 supply and potential commercial scale. This manufacturing is established at Thermo Fisher's sites in Florence, South Carolina, and Cincinnati, Ohio. This operational readiness is happening while the company manages its burn rate; cash totaled US$83.8 million as of September 30, 2025, following a US$175 million registered direct offering closed in October 2025. The net loss for the quarter ending September 30, 2025, was US$33.7 million, with cash-based operating expenses at US$28.5 million for the same period.

Here's a quick look at the pipeline focus areas:

• Advance CYB004 (GAD) Phase 2 to pivotal Phase 3.
• Invest in CYB005 for non-hallucinogenic CNS disorders.
• Develop novel, non-psychedelic-assisted therapies.
• Optimize CYB003 delivery with oral/IM options.
• Leverage Thermo Fisher Scientific for U.S. commercial-scale manufacturing.

The current state of the pipeline assets and their development status looks like this:

Program	Indication	Development Status	Key Data Point
CYB003	MDD (Adjunctive)	Phase 3 (PARADIGM: APPROACH & EMBRACE)	71% remission rate at 12 months (2x 16mg)
CYB004	GAD	Phase 2 Enrollment Complete	Topline data expected Q1 2026
CYB005	CNS Disorders	Preclinical	Secured U.S. Composition of Matter patent

The focus on delivery systems is about making the treatment fit into a provider's workflow, which is just as important as the molecule itself. Intramuscular delivery is being optimized to be more patient-friendly than existing IV methods.

Finance: review Q3 2025 cash runway against US$28.5 million quarterly operating expenses by end of next week.

Cybin Inc. (CYBN) - Ansoff Matrix: Diversification

You're looking at how Cybin Inc. can move beyond its core focus on CYB003 for Major Depressive Disorder (MDD) and CYB004 for Generalized Anxiety Disorder (GAD). The company's financial footing as of late 2025 provides a base for such moves.

Financially, Cybin Inc. reported cash totaling C$135 million as of March 31, 2025. The net loss for that fiscal year was C$113 million, driven by cash-based operating expenses of C$100 million. Cash flows used in operating activities for that year totaled C$101 million.

For the first quarter of fiscal year 2026, cash stood at $118.7 million as of June 30, 2025, with cash-based operating expenses at $23.9 million for the quarter. By the second quarter, cash was reported at US$83.8 million as of September 30, 2025, but a subsequent financing agreement in October 2025 brought the total cash position to US$248 million. The net loss for the second quarter ending September 30, 2025, was US$33.7 million.

Here's a look at the scale of the current pipeline, which informs potential integration or expansion:

• CYB003 Phase 3 APPROACH study enrollment target: 220 participants.
• CYB003 Phase 3 EMBRACE study enrollment target: 330 participants.
• Total PARADIGM Phase 3 enrollment target: approximately 550 patients.
• CYB003 Phase 2 remission rate after two 16 mg doses: 71% at 12 months.
• CYB004 Phase 2 GAD study enrollment completion expected: August 2025.

Regarding the integration of technology, Cybin Inc. already has a commercial preparation partnership with Osmind, which provides access to its 800-clinic network and point-of-care software. This partnership is intended to support the commercial preparation for the clinical-stage pipeline.

For exploring new therapeutic areas beyond core psychiatry, the company's intellectual property portfolio suggests a broader scope. Cybin Inc. holds over 100 granted patents as of August 2025, with over 250 patent applications pending. The company cited an estimated addressable market for indications including depression, anxiety disorders/PTSD, bipolar disorder, substance use/addiction, eating disorders, cluster headaches/migraine, and chronic pain management exceeding >200 million people in the U.S..

Developing a novel, non-tryptamine-based compound for a geographically untapped market like South Korea would be a significant step. The company's existing intellectual property provides exclusivity until 2041 for CYB003 and until 2040 for CYB004.

To generate near-term revenue outside the core pipeline through licensing or acquisition, Cybin Inc. completed the acquisition of Small Pharma Inc. in October 2023. This combination resulted in an intellectual property portfolio with over 30 granted patents and more than 160 patents pending at that time.

Establishing a dedicated 'Wellness' division for non-regulated services would utilize the company's current financial capacity. The cash position following the October 2025 financing was US$248 million.

The financial performance metrics related to the ongoing clinical focus are summarized below:

Metric	Year Ended March 31, 2025	Q1 Ended June 30, 2025	Q2 Ended September 30, 2025
Cash Balance	C$135 million	$118.7 million	US$83.8 million (Pre-Offering)
Net Loss	C$113 million	$24.6 million	US$33.7 million
Cash-Based Operating Expenses	C$100 million	$23.9 million	US$28.5 million
Cash Used in Operating Activities	C$101 million	$29.5 million	US$34.5 million

The operational costs for the core pipeline are substantial, as seen in the quarterly expenses:

• Cash-based operating expenses for Q2 FY2026: US$28.5 million.
• Cash flows used in operating activities for Q2 FY2026: US$34.5 million.
• Cash-based operating expenses for Q1 FY2026: $23.9 million.
• Cash flows used in operating activities for Q1 FY2026: $29.5 million.

Finance: draft 13-week cash view by Friday.